Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Ibrilatazar by Ability Pharmaceuticals for Metastatic Pancreatic Cancer: Likelihood of Approval
Ibrilatazar is under clinical development by Ability Pharmaceuticals and currently in Phase III for Metastatic Pancreatic Cancer. According to GlobalData,...